Tohoku University Technology: An inhibitor of Influenza A virus： tFIT-DPQ probe: T18-508
Over 1000 times affinity to bind with RNA virus (vs. DPQ)! Promising diagnostic and inhibitory drug!
Introduction Influenza prevails broadly every season. Current diagnostic drugs can not be performed until the virus increases quite a lot (ca. 12~24h after infection, symptoms may appear), and if not so, both sensitivity and accuracy of the test will be doubtful. To prevent on-going severe symptoms, new diagnostic tech for influenza at earlier stage becomes so demanded. This invention provides a conjugate of peptide nucleic acid sequence (PNA) and a small molecule, targeting the commonly identical RNA hairpin promoter region of eight kinds of influenza A virus. Effect & Application The conjugate (tFIT-DPQ probe) is composed of two parts: tFIT unit for recognition of virus RNA’s nucleotides and DPQ* unit for UAA internal loop binding. In tFIT unit, a fluorescent ligand is inserted so as to be capable to emit signals when intercalating to RNA duplex (Fig. 1). The conjugate shows an over 1000 times greater binding affinity than DPQ molecule only (Fig. 2). By simply mixing the virus RNA contained sample and the conjugate together, test result will be obtained within a short time (ca. 2~3 min) and 1nM virus RNA (ca. 1010 copies) can be detected. Moreover, the virus inhibition effect by the conjugate in micromolar range was confirmed (Fig. 3). tFIT-DPQ probe is expected to be applied as diagnostic and inhibitory drugs, as well as a screening tool for influenza drug candidates.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
